Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
16,112 stopped studies · 89% state a reason
Over the 16,112 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03494569 | Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell… | Phase 1 | suspended | Apr 11, 2018 | City of Hope Medical Center | Accrual goal | Enrollment / accrual |
| NCT03623464 | RCT of Mobile Apps & FitBit v. Usual Care | N/A | suspended | Aug 9, 2018 | Weill Medical College of Cornell University | Study is paused for interim analysis. | Efficacy / futility |
| NCT03833167 | Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants… | Phase 3 | terminated | Feb 6, 2019 | Merck Sharp & Dohme LLC | The study stopped due to futility | Efficacy / futility |
| NCT03834493 | Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in… | Phase 3 | terminated | Feb 8, 2019 | Merck Sharp & Dohme LLC | The study stopped due to futility | Efficacy / futility |
| NCT04191096 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen… | Phase 3 | terminated | Dec 9, 2019 | Merck Sharp & Dohme LLC | The study stopped due to futility | Efficacy / futility |
| NCT04405401 | Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer(SUPPRESS-NSCLC) | Phase 2 | terminated | May 28, 2020 | Centre hospitalier de l'Université de Montréal (CHUM) | Poor accrual | Enrollment / accrual |
| NCT05048368 | Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function | Phase 1 | withdrawn | Sep 17, 2021 | Sunshine Lake Pharma Co., Ltd. | Study was withdrawn per sponsor decision after recruitment opened with no participants enrolled. | Enrollment / accrual |
| NCT05288062 | Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a… | Phase 2 | terminated | Mar 18, 2022 | Mayo Clinic | slow accrual | Enrollment / accrual |
| NCT05642195 | Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With… | Phase 1 / Phase 2 | suspended | Dec 8, 2022 | National Cancer Institute (NCI) | Revisions to eligibility/design being made prior to enrollment of first participants. | Enrollment / accrual |
| NCT05874193 | A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma(COSTA) | Phase 2 | withdrawn | May 24, 2023 | Cristiana Costa Chase, DO | Due to barriers in anticipated accrual | Enrollment / accrual |
| NCT05932212 | AK104 for Recurrent or Metastatic Vulvar Cancer | Phase 2 | terminated | Jul 6, 2023 | Akeso | Sponsor decision | Sponsor / business decision |
| NCT06694454 | Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab… | Phase 1 / Phase 2 | suspended | Nov 19, 2024 | National Cancer Institute (NCI) | Placed on voluntary hold to new recruitment pending modification to combination monoclonal antibody… | Enrollment / accrual |
| NCT06876142 | Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory… | Phase 1 / Phase 2 | suspended | Mar 14, 2025 | National Cancer Institute (NCI) | Administrative hold pending non-safety related changes to the study design. | Safety / toxicity |
| NCT07048353 | CD30 CAR-T in the Treatment of CD30 Positive Lymphoma(CAR-T，MTD) | Early Phase 1 | suspended | Jul 2, 2025 | Shandong Qilu Cell Therapy Engineering Technology Co., Ltd | Because of changes in domestic regulations, we need to complete the local filing process first… | Other (stated, no rule matched) |
| NCT03108495 | Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients… | Phase 2 | terminated | Apr 11, 2017 | Iovance Biotherapeutics, Inc. | After reviewing available safety and efficacy data to date, Iovance concluded the study reached the… | Safety / toxicity |
| NCT04071236 | Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation… | Phase 1 / Phase 2 | suspended | Aug 28, 2019 | National Cancer Institute (NCI) | Other - To assess the study's feasibility. | Other (stated, no rule matched) |
| NCT04973007 | Comparison of Contrast Agents in Liver Magnetic Resonance (MR) for the Detection of… | Phase 4 | terminated | Jul 22, 2021 | University of Colorado, Denver | Low Accrual | Enrollment / accrual |
| NCT05629689 | A Study to Evaluate GEH200520/GEH200521 (18F) Safety and Tolerability When Used for PET… | Phase 1 | terminated | Nov 29, 2022 | GE Healthcare | GE-269-001 Part A in cancer patients was completed. Part B was significantly delayed due to slow… | Enrollment / accrual |
| NCT05886491 | A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | terminated | Jun 2, 2023 | Takeda | Sponsor decision (No safety concern) | Safety / toxicity |
| NCT06144619 | Non-Invasive Biomarkers in Prostate Cancer Disease Management | — | suspended | Nov 22, 2023 | H. Lee Moffitt Cancer Center and Research Institute | Funding unavailable | Funding |
| NCT06924606 | Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression… | Phase 2 | terminated | Apr 11, 2025 | Shanghai Junshi Bioscience Co., Ltd. | The research and development strategy was adjusted, so the research was suspended | Sponsor / business decision |
| NCT03893110 | Carbon PEEK Versus Titanium Pedicle Screws in the Treatment of Spinal Tumors | N/A | withdrawn | Mar 28, 2019 | Balgrist University Hospital | Absence of Co-investigator | Investigator |
| NCT04402788 | Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment… | Phase 2 / Phase 3 | suspended | May 27, 2020 | National Cancer Institute (NCI) | Scheduled Interim Monitoring | Other (stated, no rule matched) |
| NCT04570956 | Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular… | Phase 2 | terminated | Sep 30, 2020 | Mayo Clinic | grant and funding expired | Funding |
| NCT04671849 | An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness… | Phase 1 | terminated | Dec 17, 2020 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Business strategy | Sponsor / business decision |
| NCT04844073 | A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer | Phase 1 / Phase 2 | terminated | Apr 14, 2021 | Takeda | Sponsor decision based on limited anti-cancer activity of TAK-186. | Sponsor / business decision |
| NCT05384119 | Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone… | Phase 1 | terminated | May 20, 2022 | Tvardi Therapeutics, Incorporated | The study was terminated prior to Phase 2 due to slow accrual. | Enrollment / accrual |
| NCT05575440 | Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer | — | terminated | Oct 12, 2022 | Mayo Clinic | Slow accrual; lack of eligible study participants | Enrollment / accrual |
| NCT06071624 | Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line… | Phase 1 | suspended | Oct 6, 2023 | Huda Salman | Trial being transferred to new lead site | Other (stated, no rule matched) |
| NCT06197672 | Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory… | Phase 1 | suspended | Jan 9, 2024 | Huda Salman | Trial being transferred to new lead site | Other (stated, no rule matched) |
| NCT06290687 | Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative… | Phase 2 | withdrawn | Mar 4, 2024 | Case Comprehensive Cancer Center | PI left institution | Investigator |
| NCT06714591 | Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1 | Phase 1 | terminated | Dec 3, 2024 | SystImmune Inc. | Sponsor prioritization of other development portfolio | Sponsor / business decision |
| NCT06882746 | A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon,… | Phase 1 | terminated | Mar 19, 2025 | Boehringer Ingelheim | Sponsor decision | Sponsor / business decision |
| NCT02444936 | ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors | Phase 4 | terminated | May 15, 2015 | Louis Stokes VA Medical Center | unable to obtain samples of key groups to do any analysis. | Other (stated, no rule matched) |
| NCT03367676 | 12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative,…(SOBER) | Phase 2 | terminated | Dec 11, 2017 | Ruijin Hospital | Due to slower than anticipated enrollment, the study was terminated early after 78 patients were… | Enrollment / accrual |
| NCT05290194 | Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of… | Phase 2 | withdrawn | Mar 22, 2022 | Fifth Affiliated Hospital, Sun Yat-Sen University | The study was terminated because the protocol was upgraded after being considered insufficiently… | Other (stated, no rule matched) |
| NCT05715229 | Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated…(G360-IIT) | Phase 2 | terminated | Feb 6, 2023 | Hackensack Meridian Health | Slow Accrual | Enrollment / accrual |
| NCT06015295 | A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for… | N/A | terminated | Aug 29, 2023 | M.D. Anderson Cancer Center | \<\&%% participation | Other (stated, no rule matched) |
| NCT06485310 | Interest of a TEteleconsultation of a Psychological Support Nurse on Psychological…(TECAP) | N/A | withdrawn | Jul 3, 2024 | Centre Hospitalier Universitaire de la Réunion | The principal investigator has left the research center. | Investigator |
| NCT07052994 | A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab… | Phase 1 | withdrawn | Jul 8, 2025 | M.D. Anderson Cancer Center | PI requested | Other (stated, no rule matched) |
| NCT07708961 | Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype… | Phase 2 | suspended | Jul 16, 2026 | Mayo Clinic | Pending receipt of study drug from sponsor | Other (stated, no rule matched) |
| NCT04538378 | Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That… | Phase 2 | terminated | Sep 4, 2020 | National Cancer Institute (NCI) | Closed due to slow accrual. | Enrollment / accrual |
| NCT05477784 | Cancer Parenting Program for the Enhancement of the Quality of Life of Patients With…(EC-PC) | N/A | terminated | Jul 28, 2022 | University of Washington | Enrollment rates to the trial were lower than projected and anticipated. | Enrollment / accrual |
| NCT05629546 | Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic… | Phase 1 | suspended | Nov 29, 2022 | Washington University School of Medicine | Reviewing safety data | Safety / toxicity |
| NCT05861050 | Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients… | Phase 1 / Phase 2 | suspended | May 16, 2023 | City of Hope Medical Center | Safety Issues | Safety / toxicity |
| NCT06714617 | Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors | Phase 1 | terminated | Dec 3, 2024 | SystImmune Inc. | The decision is based only on the Sponsor's internal portfolio prioritization and resource… | Safety / toxicity |
| NCT00801151 | Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer | Phase 1 | terminated | Dec 3, 2008 | Institut Claudius Regaud | not stated | Not stated |
| NCT03891615 | Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer | Phase 1 | terminated | Mar 27, 2019 | Massachusetts General Hospital | Slow accrual. | Enrollment / accrual |
| NCT04031469 | A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease | — | suspended | Jul 24, 2019 | ProgenaBiome | Administrative | Other (stated, no rule matched) |
| NCT04601584 | GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell… | Phase 1 / Phase 2 | terminated | Oct 26, 2020 | AO GENERIUM | The sponsor discontinued the development of the drug for reasons other than safety. | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 20 hours agoSource updated Sep 28, 2026source: clinicaltrials